LUBBOCK, TX, USA, September 27, 2022 /EINPresswire.com/ -- NemaLife Inc., a techbio company focused on high throughput in vivo screening, is delighted to announce that it has received funding from the National Institute of Drug Abuse (NIDA). This new funding of $320,000 enables NemaLife to partner with companies in the growing psychedelic market by expanding the capabilities of its technology platform to screen for therapeutics for neurobehavioral disorders using a tractable biological model, the worm C. elegans.